A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus) and Peginterferon Alfa 2a (Pegasys) in Treatment Na�ve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection The primary objective of this study is to evaluate the antiviral efficacy (sustained virologic response [SVR]; defined as undetectable HCV RNA 24 weeks following treatment cessation) of 16 and 24 week...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A trial investigating the safety and efficacy of a drug combination Sofosbuvir/Velpatasvir for subjects with hepatitis C To evaluate the efficacy of study treatment with sofosbuvir (SOF)/velpatasvir (VEL) FDC for 12 weeks as measured by the proportion of subjects with sustained virologic response 12 weeks after cessatio...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An investigational study to assess the safety and efficacy of a new investigational drug in subjects with compensated liver cirrhosis secondary to non-alcoholic steatohepatitis (NASH) To evaluate whether simtuzumab (formerly referred to as GS-6624) can reduce portal venous pressure and incidence of clinical events in subjects with cirrhosis due to NASH.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A long-term study to follow cirrhotic patients infected with chronic Hepatitis C who achieved a cure following treatment in a Gilead clinical trial To assess the durability of SVR; To assess clinical progression or regression of liver disease, including the incidence of hepatocellular carcinoma (HCC) following SVR.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to evaluate the effects of the combination of 4 oral antiviral agents for the treatment of patients infected with the Hepatitis C Virus (HCV) To evaluate the antiviral efficacy as measured by sustained virologic response (SVR, defined as HCV RNA < LLoQ 24 weeks post-treatment) of 30 mg or 90 mg GS-5885 when given with GS-9451, tegobuvir and...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

This trial will test the drug filgotinib for the treatment of small bowel Crohn’s disease The primary objective of this study is to evaluate the efficacy of filgotinib, when compared to placebo, in establishing clinical remission at Week 24

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to Evaluate GS-5806 in Volunteers Infected with Respiratory Syncytial Virus The primary objective of the study is to evaluate the antiviral effect of GS-5806 in healthy adults infected with RSV-A Memphis 37b (RSV).

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study is to see if HIV-1 positive subjects currently taking an antiretroviral (ARV) regimen consisting of EVG/COBI/FTC/TDF (E/C/F/TDF) STR, Atripla® (also known as Sustiva®), cobicistat and atazanavir with Truvada® or ritonovir and atazanavir with Truvada® can safely switch to E/C/F/TAF STR without increasing the amount of HIV-1 in their blood The primary objective of this study is: • To evaluate the non-inferiority of switching to a TAF-Containing STR relative to maintaining TDF-Containing Regimens in Virologically-Suppressed HIV-1 positi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. Estudio para evaluar la seguridad y eficacia de selonsertib en pacientes con esteatohepatitis no alcohólica (EHNA) y fibrosis en puentes (F3) The primary objective of this study is: To evaluate whether SEL can cause fibrosis regression and reduce progression to cirrhosis and associated complications in subjects with NASH and bridging (F3) f...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study evaluating the safety and efficacy of the combination of GS-4059 and idelalisib with and without obinutuzumab in subjects with chronic lymphocytic leukemia The primary objective of this study is to determine the preliminary efficacy of the combination of GS-4059 and idelalisib with and without obinutuzumab in subjects with relapsed or refractory CLL

• Pays Aucun
• Organes Aucun
• Spécialités Aucune